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Abstract: Although  the risk of acquisition of hepatitis B or hepatitis C virus th
products has considerably reduced since the last decade, some infected patients are candidates 
to stem cell transplantation. Others may have no alternative than an infected donor. In all 
these cases, recipients of transplant are prone to short 
evolution of liver tests under chemotherapy before transplant may give useful information to 
anticipate on  the risk of hepatitis reactivation after transplant, both for HBv and HCv. More 
than sixty percent of the patients who are HBsAg
transplant,  and  3%  develop  acute  severe  liver failure.  Because  both viral  replication  and 
immune reconstitution are the key factors for reactivation, it is crucial to closely follow liver 
function  tests  and  viral  load  during  the  first  months  of  transplant,  and  to  pay  a  special 
attention in slowly tapering the immunosuppression in these patients. Lamivudine reduces 
HBv  viremia,  but  favors  the  emergence  of  HBv  polymerase  gene  mutants  and  should  b
individually discussed. Both in case of HBv or HCv hepatitis reactivation with ALT 
concomitantly to an increase in viral load at time of immune reconstitution, steroids should be 
given. In case there is no alternative than a HBv or HCv positive gen
risk of viral hepatitis, including acute liver failure and late complications, should be balanced 
with the benefit of transplant in a given situation. 
Introduction:  The  occurrence  of  infection  with 
Hepatitis B (HBV) or Hepatitis C virus (HCV)  in 
patients undergoing allogeneic or autologous stem 
cell  transplantation  (HSCT)  poses  several  clinical 
problems,  as  these  infectious  complications  can 
jeopardize  the  ultimate  prognosis,  due  to  the 
possibility  of  progression  to  fulminant  hepatic 
failure  and  also  to  possible  evolution  to  chronic 
active hepatitis and cirrhosis. Although the risk of 
acquiring  HBV  and  HCV  infection  from  blood 
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Although  the risk of acquisition of hepatitis B or hepatitis C virus th
products has considerably reduced since the last decade, some infected patients are candidates 
to stem cell transplantation. Others may have no alternative than an infected donor. In all 
these cases, recipients of transplant are prone to short and long term liver complications. The 
evolution of liver tests under chemotherapy before transplant may give useful information to 
anticipate on  the risk of hepatitis reactivation after transplant, both for HBv and HCv. More 
ients who are HBsAg-positive before transplant reactivate after 
transplant,  and 3%  develop  acute  severe  liver  failure.  Because  both viral  replication  and 
immune reconstitution are the key factors for reactivation, it is crucial to closely follow liver 
tion  tests  and  viral  load  during  the  first  months  of  transplant,  and  to  pay  a  special 
attention in slowly tapering the immunosuppression in these patients. Lamivudine reduces 
HBv  viremia,  but  favors  the  emergence  of  HBv  polymerase  gene  mutants  and  should  b
individually discussed. Both in case of HBv or HCv hepatitis reactivation with ALT 
concomitantly to an increase in viral load at time of immune reconstitution, steroids should be 
given. In case there is no alternative than a HBv or HCv positive geno-identical donor, the 
risk of viral hepatitis, including acute liver failure and late complications, should be balanced 
with the benefit of transplant in a given situation. 
The  occurrence  of  infection  with 
Hepatitis B (HBV) or Hepatitis C virus (HCV)  in 
patients undergoing allogeneic or autologous stem 
cell  transplantation  (HSCT)  poses  several  clinical 
problems,  as  these  infectious  complications  can 
e  the  ultimate  prognosis,  due  to  the 
possibility  of  progression  to  fulminant  hepatic 
failure  and  also  to  possible  evolution  to  chronic 
active hepatitis and cirrhosis. Although the risk of 
acquiring  HBV  and  HCV  infection  from  blood 
transfusion  is  nowadays  greatly  reduced,  HSCT 
patients still represent a group at high risk, being 
prone  to  becoming  infected  due  to  the  lack  of 
immune competence given both the hematological 
disease and the conditioning regimen they receive 
before HSCT. Moreover, these patients m
be  infected  at  transplant.  Lastly,  patients  under
going allogeneic HSCT may have a single related 
donor  who  is  an  HBV  or  HCV  carrier,  and  this 
event  is  far  from  exceptional,  especially  in 
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Although  the risk of acquisition of hepatitis B or hepatitis C virus through blood 
products has considerably reduced since the last decade, some infected patients are candidates 
to stem cell transplantation. Others may have no alternative than an infected donor. In all 
and long term liver complications. The 
evolution of liver tests under chemotherapy before transplant may give useful information to 
anticipate on  the risk of hepatitis reactivation after transplant, both for HBv and HCv. More 
positive before transplant reactivate after 
transplant,  and  3%  develop  acute  severe  liver  failure.  Because  both viral  replication  and 
immune reconstitution are the key factors for reactivation, it is crucial to closely follow liver 
tion  tests  and  viral  load  during  the  first  months  of  transplant,  and  to  pay  a  special 
attention in slowly tapering the immunosuppression in these patients. Lamivudine reduces 
HBv  viremia,  but  favors  the  emergence  of  HBv  polymerase  gene  mutants  and  should  be 
individually discussed. Both in case of HBv or HCv hepatitis reactivation with ALT > 10N 
concomitantly to an increase in viral load at time of immune reconstitution, steroids should be 
identical donor, the 
risk of viral hepatitis, including acute liver failure and late complications, should be balanced 
reatly  reduced,  HSCT 
patients still represent a group at high risk, being 
prone  to  becoming  infected  due  to  the  lack  of 
immune competence given both the hematological 
disease and the conditioning regimen they receive 
before HSCT. Moreover, these patients may already 
be  infected  at  transplant.  Lastly,  patients  under-
going allogeneic HSCT may have a single related 
donor  who  is  an  HBV  or  HCV  carrier,  and  this 
event  is  far  from  exceptional,  especially  in Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
geographic areas where these viruses are endemic. 
The  behavior  of  HBV  and  HCV  infection  and 
related disease is often unpredictable in this cohort 
of  patients  both  in  the  short-term  and  long-term 
outcome. 
Hepatitis  B  Virus  Infection  and  Related  Liver 
Disease
Biology and  Pathogenesis of  Hepatitis B  virus: 
HBV  is  a  DNA  virus  classified  in  the  EPADNA 
Virus  Family.  Its  molecular  organization  and 
replication  mechanisms  have  been  extensively 
characterized 
1. The virus replicates in hepatocytes 
with high efficiency and viral replication produces a 
large amount of viral particles with high level of 
viraemia. HBV is also able to integrate its genome 
into  the  host  DNA  and  produces  a  number  of 
structural  and  non-structural  proteins  which 
modulate the virus-cell interactions. Some of these 
proteins  have  regulatory  and  transcriptional 
functions which control gene expression  and may 
be  involved  in  hepato-carcinogenesis.  The 
replicative phase of HBV infection is characterized 
by the presence of a soluble viral protein (HbeAg) 
and of HBV-DNA in serum. Seroconversion to anti-
Hbe characterizes the transition from the replicative 
into  the  non-replicative  phase  (integration  phase) 
and  is  usually  associated  with  disappearance  of 
viraemia.  These  events  have  clinical  relevance  as 
they associate with remission of liver-cell damage, 
indicating that virus replication is a pre-requisite for 
triggering hepato-cellular injury. Complete recovery 
from  HBV  infection  is  associated  with 
seroconversion  from  HbsAg  positive  to  antiHBs 
positive  status.  In  the  past  decade,  accumulating 
evidence indicates that some patients may become 
chronically infected with HBV with persistent virus 
replication  in  the  absence  of  HbeAg  in  serum. 
These cases are infected by HBV pre-core mutants 
that  replicate  persistently  while  not  secreting 
HbeAg, due to point mutations in the coding region. 
HBV is not considered to be directly cytopathic in 
the  immune-competent  host  and  most  evidence 
supports  the  conclusion  that  the  host-immune 
response plays a major role in the pathogenesis of 
HBV-related  liver  damage.  However,  in the 
presence of exceptionally high virus replication and 
expression of virus products in the infected cells, a 
direct cytopathic mechanism may also supervene
2,3. 
The  current  interpretation  of  HBV  immune-
pathology explains liver-cell damage as the result of 
reactivity of virus-specific cytotoxic T lymphocytes 
recognizing  epitopes  of  the  core  or  the  envelope 
antigens on the surface of infected hepatocytes. The 
release of high concentration of soluble cytokines in 
the  liver  may  also  contribute  to  amplification  of 
liver damage. The pathogenesis may be somehow 
different  in  patients  infected  by  HbeAg  negative 
pre-core mutants, which are often associated with 
more severe flare-ups of liver damage.
Natural  course  of  hepatitis  B  in  the 
Immunocompetent  Host:  HBV  infection  is 
responsible for acute hepatitis, which may develop 
into a fulminant course in 1% of cases, or progress 
to chronic infection in 5-10%. Chronic hepatitis B 
shows  variable  histological  activity,  that  may 
eventually lead to cirrhosis in 20-40% of patients.  
Further  progression  includes  decompensated  liver 
disease and death for liver-related causes. Carriers 
of  HBV  have  a  300-fold  increased  risk  of 
developing hepatocellular carcinoma (HCC). Most 
HBV  carriers,  however,  have  never  developed 
severe liver complications during their lifetime. The 
current treatment for chronic hepatitis B is based on 
the  use  of  interferon  and    nucleotide  analogues 
(mostly  lamivudine,  but  also  adefovir,  lobucavir 
and  others).  The  sustained  response  rate  after  6 
months  of  treatment  is  between  20  and  40%. 
However, eradication of infection is rarely achieved 
and  HBV  often  reactivates  when  therapy  is 
withdrawn.Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Acute events and risk factors of HBV infection 
early  post  Hematopoetic  Stem  Cell 
Transplantation (HSCT): The prevalence of HBV 
infection  in  patients  undergoing  HSCT  differs 
according to geographic areas, and ranges from 1% 
to  28%  in  published  reports  (Table  1)
5-9.  In  a 
prospective  study  including  15  HSCT  European 
units,  six  out  of  193  patients  (3%)  treated 
consecutively  were found HbsAg  positive  before 
HSCT
10 thus  confirming  that  HBV  infection  still 
represents a clinical problem in this setting.
An  acute  exacerbation  of  liver  disease 
following  immune  reconstitution  occurs  in  more 
than 60% of cases. Data derived from a multicenter 
study
11 show that the risk of hepatitis B reactivation 
at 24 months after HSCT was 81%  for allogeneic 
and  66%  for autologous cases (p = 0.3). As to the 
timing,  the  majority  of  patients  had  a  clinical 
exacerbation of liver damage within the first year 
post-transplant.  Interestingly,  in  the  autologous 
group a   majority of  patients showed  ALT peaks 
within six months after HSCT, while  most patients 
undergoing  allogeneic  transplant  did  so  later  on.  
Reactivation can be followed by complete recovery 
and seroreversion to HbsAg negative status in one 
fourth  of  cases,  even  without  antiviral  therapy
12, 
while  a  fulminant  evolution  occurs  in  a  smaller 
proportion of patients (3%)  As to the outcome of 
post-SCT hepatitis, the majority of reports indicates 
that  the  disease  is  often  mild  and  asymptomatic, 
with  moderate  but  long-lasting  transaminase 
abnormalities
5,6,7. The profound impairment of the 
immune response can also influence the serological 
profile, which is often bizarre: in HbsAg positive 
patients, serum antibodies to HbcAg are frequently 
absent,  even  in  cases  with  high-level  HBV 
replication and also in some cases receiving a bone 
marrow from an anti-HBc positive donor
5. Failure 
to  develop  anti-HBc  in  these  cases  may  be  the 
consequence  of  intrinsic  B-cell  defect  or  of 
excessive  suppressor  T  cell  activity,  which  are 
known to deeply influence the process of immune 
reconstitution following SCT. On the other hand, a 
transient  appearance  of  HBV  antibodies  after 
transplant  is  frequent,  also  in  cases  with  no 
evidence  of  HBV  infection,  likely  due  to  passive 
immunization via blood products admini-stered: in 
a pediatric prospective study we observed that more 
than 90% of children had detectable antibodies in 
serum  after  transplant,  which  disappeared  during 
follow-up in more than half of them
13.
“De  novo”  HBV  infection:  risk  factors  and 
related  liver  disease:  Patients  undergoing  HSCT 
can  develop  a  “de  novo”  HBV    infection  post-
transplant,  and  the  overall  frequency  of  such  a 
complication,  diagnosed  by  means  of  HbsAg  and 
HBV-DNA  seroconversion,  was  reported  to  be
around 3%
10. Sometimes the origin of the infection 
is  evident,  such  as  in  case  of  positive  stem  cell 
donors, but in the majority of cases the modalities 
of  transmission  are  less  obvious,  especially 
considering  that  all  blood  products  are  nowadays 
screened for HBV serum markers. In a recent study 
including  24  patients  receiving  HBV  infected 
marrow, HbsAg became detectable in 22% of pre-
BMT  negative  recipients,  but  only  5.5%  became 
chronic  carriers
24.  Antigenemia  developed  more 
frequently in anti-HBs negative compared with anti-
HBs positive patients. Fatal liver failure occurred in 
21% of cases. Patients with an anti-Hbe donor had a 
higher frequency of liver failure (28% versus 0%) 
and higher transaminase peak values compared to 
HbeAg  positive  donors.  Liver  failure  was  never 
observed  in    anti-HBs  positive  recipients.  The 
observation that the rate of seroconversion is lower 
than  expected  in  case  of  positive  donor  was 
confirmed in a prospective study by the Infectious 
Diseases Working Party of the European Blood and 
Marrow Transplantation  Group
10. Of four patients 
receiving BMT from an HbsAg positive donor, only 
two became HbsAg positive. Liver disease in these 
patients  was  minimal  and  none  suffered  from 
fulminant  hepatitis.  In  the  same  study,  the 
prevalence of “de novo” HBV infection in patients 
transplanted  with  an  HbsAg  negative  donor  was 
2%,  and  also  in  these  patients,  the  HBV-related 
liver disease was clinically  benign. The observation 
that  before  HSCT  2  out  of  13  anti-HBc  positive 
patients became HbsAg positive during follow-up, 
compared  to  2  out  157  anti-HBc  negative  cases, 
poses the question whether these episodes were true 
“de  novo”  rather  than  reactivation  of  latent 
infection,  an  event  already  reported  in  the 
literature
25.
Long-term sequelae of Hepatitis B infection after 
Hematopoietic  Stem  Cell  Transplantation: 
Patients infected with HBV generally show a mild 
to moderate liver disease on long-term follow-up, 
and cirrhosis due to chronic B hepatitis has not been 
reported to date. 
It should be stressed that flares in transaminases 
after  HSCT,  even  in  the  presence  of  viraemia, 
doesn’t    automatically  translate  in  viral  hepatitis 
reactivation,  as  other  causes  ,  such  GVHD,  iron 
overload,  and  other  infections,  can  result  in  this 
clinical picture. In these cases, liver biopsy should 
be considered,Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Hepatitis C Virus Infection And Related  Liver 
Disease
Biology and  pathogenesis  of  Hepatitis C virus: 
HCV  is  a  double-stranded  RNA  virus  classified 
within  the  Flaviviridiae  . The  virus  consists  of  a 
family of closely related while genetically distinct 
types and subtypes. Six major genotypes have been 
identified and classified, from HCV1 to HCV6. The 
mechanisms  of  replication  of  HCV  and 
pathogenesis  of  the  associated  liver  disease  have 
been only partially characterized. The infection has 
a high propensity to becoming chronic, due to the 
high mutation rate of the envelope region coding for 
the  surface  antigens  allowing  the  virus  to  easily 
escape to the host-immune response. As for HBV, 
liver  damage  in  hepatitis  C  is  thought  to  be 
dependent  mainly  on  the  host-immune  response 
mediated  by  cytotoxic  T  cells.  HCV  infection  is 
responsible  for  hepatic  and  extra-hepatic  disease. 
The  extra-hepatic  mani-festations  include  chronic 
fatigue,  cryo-globulinemia,  vasculitis  and 
autoimmune  disorders.  These  manifestations  are 
most likely due to direct interaction of HCV with 
the  immune  system  through  the  CD81  receptor
4. 
Monoclonal  expansion  of  B  cells  may  occur, 
leading  to  low-grade  B-cell  lymphoma. HCV 
replication  is  significantly  increased  by 
immunosuppression and, as in hepatitis B, it may 
trigger a direct cytopathic effect in infected cells. 
Immune  complexes-mediated  immunopathology 
may also be relevant in hepatitis C.
Natural  course  of  hepatitis  C  in 
Immunocompetent host: Acute hepatitis C is often 
asymptomatic  and  mild  and  is  rarely  recognized 
clinically.  A  fulminant  or  severe  course  is 
exceptionally rare in the absence of cofactors or of 
coinfections. On the other hand, chronic carriers of 
HCV might  be  particularly  prone  to  develop 
fulminant hepatitis when superinfected by Hepatitis 
A  Virus  (HAV)  or  other  hepatotropic  agents. 
Hepatitis C becomes chronic in 60-80% of infected 
individuals  and  very  few  of  them  are  healthy 
chronic  carriers,  while  most  show  histological 
evidence  of  chronic  hepatitis.  Chronic  hepatitis 
progresses  to  cirrhosis  in  20-40%  of  the  cases 
within  10-20  years  after onset. The major  factors 
that  increase  the  risk  of  progression  are:  age, 
alcohol  abuse,  coinfection  with  HBV  or  HIV, 
immunosuppression,  and  iron  overload.  After 
cirrhosis has developed, decompensation occurs and 
HCC may develop with an annual incidence of 3%.
The current treatment for hepatitis C is based on 
the  combination  of    Interferon  alpha  with  the 
nucleotide analogue Ribavirin for 12 months. This 
therapy  produces  a  rate  of  sustained  response 
ranging from 10% to 40%, depending on the HCV 
genotype and pretreatment virus load. 
Before  the  routine  screening  of  blood  donors 
was introduced, the prevalence of HCV infection in 
HSCT recipients, based on the detection of specific 
antibodies, was reported to range from 10% up to 
30%
13,14,15.  These  figures  certainly  underestimated 
the  problem,  as  in  these  patient  populations  the 
diagnostic  sensitivity  of  anti-HCV  is  particularly 
low in the presence of immunosuppression, thus the 
only  method  to  identify  HCV  infection  is  the 
detection  of  HCV-RNA.  Although  the  risk  of 
transfusion-associated  transmission  has 
dramatically  decreased  in  the  last  decade,  the 
problem is still present. In a pediatric series, 25% of 
children  transplanted  before  1990  - when  HCV 
screening for blood donor was introduced in Italy -
were found anti-HCV positive, but afterwards 15% 
of cases were still found infected
16. More recently, 
results  derived  from  a  prospective  study  showed 
that  6%  of  HSCT  candidates  were  HCV-RNA 
positive before transplant: only half of them were 
also positive for anti-HCV
10 .The identification of 
pre-transplant  HCV  infection  appears  clinically 
relevant: besides the possibility of viral reactivation 
and  hepatitis  exacerbation  following  immune 
reconstitution and the risk of chronic evolution and 
cirrhosis,  being  infected  with  HCV  has  been 
indicated  as  an  independent  risk  factor  for  post-
transplant  veno-occlusive  disease  of  the  liver
17,18. 
This relationship, however, is controversial, as other 
investigators did not find such an association either 
in retrospective or in prospective studies including 
both  pediatric  and    adult  populations
10,13,19,20,21. 
Reactivation  of  chronic  HCV  infection  after 
tapering  immunosuppressive  medication,  some-
times leading to fulminant hepatic failure, has also 
been reported
22,23, thus emphasizing the role of an 
immune mediated mechanism in the patho-genesis 
of HCV-related liver disease. Data derived from an 
Italian  multicenter  study
11 show  that  the  risk  of 
hepatitis C reactivation at 24 months after HSCT 
was 100% for allogeneic and  16%  for autologous 
cases
11.    Figure 2 shows  the  type  of  post-HSCT 
liver  disease  occurring  in  HCV  infected  patients 
undergoing  autologous  or  allogeneic  HSCT.  The 
risk  of  death  after  reactivation  was  8%,  and  was 
observed  only  in  allogeneic  setting,  while  the 
probability of complete resolution of liver disease 
after  reactivation  was  67%  and  48%  in  allo  or Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
autologous  transplant  respectively
11.  When  HBV 
and  HCV  positive  patients  were  compared,  some 
interesting  differences  in  the  ALT  profiles 
following  auto-logous  and  allogeneic  HSCT  were 
observed.  In  HCV  positive  cases,  ALT  elevation 
was more frequent, severe and protracted following 
allogeneic graft compared to autologous transplant.  
When  the  course  of  reactivation  was  benign, 
recovery  from  liver  disease  was  more  frequently 
seen in allogeneic compared to autologous HSCT. 
Therefore  in  HCV  infection  other  factors  may 
influence  the  profile  of  liver  disease,  such  as 
immune  suppression,  conditioning  regimen  and 
GVHD prophylaxis, donor immunity and, possibly, 
the GVH reaction .
“De  novo”  HCV  infection, risk  factors  and 
related  liver  disease:  Patients  undergoing  HSCT 
can  develop  a  “de  novo”  HCV  infection  post-
transplant,  and  the  overall  frequency  of  such  a 
complication,  diagnosed  by  means  of  HCV-RNA 
seroconversion,  was  reported  to  be  around  7%
10. 
Sometimes  the  origin  of  the  infection  is  evident, 
such as in case of positive stem cell donors, but in 
the majority of cases the modalities of transmission 
are  less  obvious,  especially  considering  that  all 
blood  products  are  nowadays  screened  for  HCV 
serum markers The prevalence of   “de novo” HCV 
infection in the latter  study  was around 7%: in 2 
cases  the  infection  was  transmitted by  a  positive 
stem  cell  donor
10.  Interestingly,  only  2  out  of  4 
patients  receiving  an  infected  marrow  became 
viraemic,  while  Shuhart  et al.  have  observed  a 
100% rate of transmission in such cases
14. Shuhart 
also reported that viraemia occurred within a few 
days  after  HSCT,  none  cleared  the  virus  and  the 
acute illness was subclinical in all cases while in 
our study we observed that seroconversion occurred  
within 15-180 days, with 40% of patients suffering 
from  severe  hepatitis  being  fatal  in  one  case
10. 
When  the  transplant  procedure can be  postponed, 
HCV transmission via stem cells may be prevented 
by  treating  the  donor  with  interferon,  that  could 
eliminate viremia within three months
26. However, 
the withdra of   such a therapy at least two weeks 
before harvest should be considered, as interferon  
might  influence  HSCT  outcome,  affecting    both 
quality of SC harvest and take
27,28.
These  contradicting  data  indicate  that  more 
information  is  needed  to  carefully  establish  firm 
conclusions  and  recommendations  in  this  special 
patient  setting,  and  that  the  risk  in  individual 
patients is difficult to predict.
Long-term sequelae of Hepatitis C infection after 
hematopoietic  Stem  cell  Transplantation: 
Patients infected with HCV generally show a mild 
to  moderate  liver  disease  on  long-term  follow-
up.Chronic  C  hepatitis,  it  is  often  asymptomatic, 
with  biochemical  abnormalities  characterized  by  
fluctuation  in  transaminase  levels,    ranging  from 
normal to abnormal values over time, with no signs 
or symptoms of decompensated liver disease at least 
during  the  first  decade  following  HSCT
13,18,19,20.  
Recently,  the  Seattle  group  has  reported  a 
progression  to  cirrhosis  and  decompensated  liver 
disease in some patients observed for more than ten 
years 
18,27.  The Saint Louis group published results 
on 96 patients  infected with HCV  between 1973 
and 1995 ,with a median follow-up of more than 15 
years: the cumulative incidence of  progression to 
cirrhosis was 11% at 15 years  and 24% at 20 years. 
Genotype  3  was  found  an  additional  risk  factor, 
while  extrahepatic  manifestations,  such  as 
cryoglobulinemia,  thrombocytopenia,  neurological, 
and  renal  manifestations,  had  no  significant 
impact.
28 . 
It should be stressed that,also in patients with 
HCV  infection,  (  like  those  with  HBV  )flares  in 
transaminases after HSCT, even in the presence of 
viraemia,  doesn’t    automatically  translate  in  viral 
hepatitis reactivation, as other causes , such GVHD, 
iron overload, and other infections, can result in this 
clinical picture. In these cases, liver biopsy should 
be considered,
These  clinical  observations  indicate  that, 
although the outcome of this chronic hepatitis does 
not seem to be significantly influenced by transplant 
procedures, it may represent an important clinical 
problem in long-term survivors. 
-Whenever possible, pretransplant liver biopsy 
should be considered in case of clinical evidence of 
chronic  liver  disease,  alcohol  abuse  (which 
enhances the risk of hepatic fibrosis), documented 
long-lasting    active    C  hepatitis  (more  than  10 
years). Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
-HSCT  patients  who  are  HbS  Ag  positive  or 
HCV positive, or who received a transplant from a 
positive  HBV  or  HCV  donor  should  be  closely 
monitored  for  liver  function  tests  (LFT’s),  and 
especially transaminases, and HBV or HCV serum 
markers  at  least  every  two weeks  from  stem cell 
infusion  up  to  three  months  ,  every  3  months 
thereafter  for  the  first  year  post-transplant,  and 
every 6 months thereafter, with no therapy required 
in case of normal  results. 
-Both  in  HBsAg  positive  or  HCV  positive 
allogeneic  transplant  patients  it  is  crucial  to 
carefully  taper  the  immunosuppressive  therapy 
post-transplant,  in  order  to  avoid  severe  hepatitis 
reactivation.
-Similarly, if there is a flare up of hepatitis  in 
case  or  HCV or  HBV  (ALT   500  U/L together 
with documented increased viral load),  the addition 
of  immunosuppressive  therapy  with  close 
monitoring of LFTs, is strongly recommended, to 
lower  the  risk  of  evolution  to  fulminant  hepatic 
failure REF).
Hbv Infection
In case of  ALT flares during follow-up (ALT 
10-20  fold  upper  normal  value)    together  with 
documented  increased  viral  load,  either  after 
allogeneic, or autologous transplant, treatment with 
lamivudine  100  mg    in  a  single  daily  oral 
administration for 12 months (alternative in case of 
no  oral  uptake: ganciclovir  10  mg/kg/day  i.v.) 
should be considered. Administration of lamivudine 
results in rapid and profound suppression of HBV 
replication  preventing  flares  of  viraemia  and  the 
risk  of  life-threatening  liver  disease.  Moreover, 
lamivudine has no major side effects. However, we 
do  recommend  a  careful  use  of  this  drug  in 
transplant  setting,  as    viraemia  rapidly  reappears 
after  withdrawal  of  lamivudine  together  with
possible hepatitis recurrence
29. This could happen if 
oral  uptake  becomes  impossible  for  any  reason. 
Additionally,  prolonged  therapy  with  this  drug  is 
followed  by  the  emergence  of  HBV-DNA 
polymerase mutants that may not be free of serious 
clinical  consequences.  As  the  selection  of  these 
mutants is time-dependent, the indication for long-
term  therapy  should  balance  the  expected  benefit 
against the risk that the clinical course may, instead, 
be  worsened  by  the  emergence  of  mutants.  The 
combination  of  lamivudine  and  anti-HBs  
immunoglobulins  has  also  been  adopted  in  other 
risk  situations,  such  as  liver  transplants,  with  
encouraging  results.  The  usual  schedule  of 
administration for Hepatitis B Ig G is:  5000 U /day 
i.v.  per dose, given every two  weeks,  starting on 
day 0 (SC infusion) for three times, and then every 
month for six months  or more if clinically indicated 
(hepatitis flares).
Several Settings Should Be Distinguished
a)  Auto  HSCT  in  HBsAg  positive  patients: For 
these patients, the past-history of liver disease and 
viral  load  (eg  ;  clinical  reactivation  of    hepatitis 
during  the  intervals  between  courses  of 
chemotherapy)  is  of  paramount  importance  to 
anticipate on the course after transplant.  If hepatitis 
worsened  between  CT  courses  or  after  CT 
withdrawal,  the  patient  is  likely  to  have  further 
exacerbation of hepatitis (reactivation) after HSCT.
If  case of normal or slightly abnormal ALT at 
HSCT  ,  and  no  reactivation  during  previous  CT:
accurate  monitoring  of    LFT’s  especially  after 
HSCT  engraftment  and  from  3  to  6  months 
afterwards (immune-reconstitution).  If there is no 
post-HSCT  liver  disease,  then  no  therapy  is 
required. 
 If  ALT  deteriorates  during  follow-up  (ALT  
500 U/L)  together with documented increased 
viral load) Lamivudine (or ganciclovir in case of 
impossible  oral  take)  should  be  administered, 
combined with Hepatitis B IgG.
In case of abnormal ALT at SC, with previous 
reactivation  during  CT: The  association  of 
lamivudine (or ganciclovir) and Hepatitis B IgG is 
also recommended. 
If there is a flare up of hepatitis, an addition of 
immunosuppressive therapy with corticosteroids, to 
be  tapered  very  slowly  could  be  considered 
followed by close monitoring of LFT’s, to reduce 
the  risk  of  evolution  to  fulminant hepatic  failure. 
Firm data on the steroid dosage to be used in this 
clinical  setting  are  not  available,  although  most 
clinicians  use  2  mg/kg/day  for  the  first  2  weeks, 
followed by careful and slow tapering. Recently, a 
schedule  of  60  mg/day  for  4  days  and  until 
prothrombin time  has  stabilized ,  followed by 10 
mg  reduction  every  four  days  up  to  30  mg,  and 
eventually  a daily  reduction  of  2.5-5 mg every 2 
weeks,  according  to  transaminases  behavior  has 
been published
30.
b)  Allo  HSCT  in  HBsAg  positive  patients: 
Lamivudine  and  Hepatitis  B  IgG  should  be 
administered  as  for  autologous  HSCT  and 
according to the same modalities. In addition, post-
transplant  immunosuppressive  therapy  should  be Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
carefully  tapered,  because  of  the  risk  of  acute 
reactivation in case of abrupt discontinuation.
c)  Allo  HSCT  in  patients  HBsAg  negative  with 
HBsAg positive donor: Although quite exceptional, 
it may happen that the only HLA-identical sibling 
donor  for  a  HBsAg  negative  leukemic  patient  is 
HBsAg  positive.  Choosing  between  such  a  donor 
versus an unrelated HBsAg negative donor should 
be carefully considered according to the risk of liver 
complications versus the risk of more GVHD and 
more  transplant-related  mortality  in  unrelated 
transplants.  If  the  stem  cell  donor  is  HBsAg 
positive,  bone  marrow  stem  cells  instead  of 
peripheral  SCs,  is  preferred  .  since  the  latter 
theoretically brings a higher viral load and higher 
risk  for  acute  and  chronic  GVHD.  On  the  other 
hand, this risk should be compared with the possible 
benefit of more graft versus leukemia effect derived 
from peripheral hematopoietic stem cells, mainly in 
patients transplanted in leukemia relapse. Different 
strategies have been proposed in order to reduce the 
risk of HBV infection in the recipient:
- administration  of  anti-HBs  immuno-globulins, 
together with HBV vaccination  in the recipient: 
although  this  strategy  has  no  major 
complications,  the  efficacy  to  prevent    HBV 
transmission  has  never  been    clearly 
demonstrated.
- Donor  treatment  with  lamivudine    before 
donation:  although  this  approach  seems  quite 
safe for the recipient, there are still no available 
published  data  to  support  this  assumption. 
Donor  health  should  also  be  considered: 
Lamivudine treatment should be initiated only 
if clinically indicated for the donor .
In case of seroconversion following transplant 
(from HBV-DNA negative to HBV-DNA positive  
and/or  HBsAg  negative  to  HBsAg  positive), 
lamivudine (or ganciclovir i.v.) are recommended.
If  there  is  clinical  hepatitis,  immune-
suppressive  therapy  with  corticosteroids  as
described above should be given
Hcv Infection
a) Auto or Allo-HSCT in patients with HCV-RNA  
in  serum    (  with  or  without  anti-HCV): Again, 
careful consideration of the clinical course of liver 
disease during CT may help for the management of 
the  post-HSCT  course.  If  normal  or  slightly 
abnormal ALT at SC , without any post-HSCT liver 
disease, then no particular measures are required. If
ALT increases during follow-up (ALT  500 U/L 
together with documented increased viral load) or 
clinical hepatitis exacerbation, it is recommended to 
add  immunosuppressive  therapy,  with 
corticosteroids  to  be  tapered  very  slowly,  with  a 
close monitoring of LFT’s, to prevent evolution to 
fulminant hepatic failure.
Additionally,  to  prevent  hepatitis  A  virus  co-
infection, it is recommended to administer purified 
hepatitis  A  inactivated  vaccine,  prior  to  SC 
transplant and at day +28 post-infusion
31.
b)  Allo-HSCT  in  patients  HCV-RNA  neg  with 
HCV-RNA or anti-HCV positive donor: This is an 
exceptional situation, and donor liver disease should 
be  investigated  (LFTs  and  liver  biopsy).  If  
interferon therapy is indicated for the donor and it is 
possible  to  postpone  HSCT  without  major 
consequences for the patient, the possibility should 
be considered  to treat the donor with IFN  or with 
IFN  plus  ribavirin  for  1-3  months,  in  order  to 
reduce  amount  of  virus  transferred  to  the  HSCT 
patient
26. Therapy should be withdrawn  within two 
weeks  before  SC  harvest.  If  there  is  clinical 
hepatitis related to HCV infection in the recipient 
after  HSCT  (seroconversion  from  HCV-RNA 
negative  to  HCV-RNA positive):  corticosteroid 
therapy  is  indicated,  according  to  treatment 
schedule  criteria already described.
Whatever  the  source  or  modalities  of  HCV 
infection (de novo, related or not to donor serology, 
pretransplant  HCV  positive  patient)  one  should 
always  keep  in  mind  that  post-transplant  liver 
disease can be due to multiple concomitant causes . 
In this  respect,  besides  viral hepatitis (  also from 
viruses  other  than  HCV),  hepatic  GVHD,  drug 
toxicity, parenteral nutrition, iron overload, fungal 
infections,  and other  less  common  causes, should 
always  be  considered.  Liver  biopsy  should be 
performed, to help in differential diagnosis, before 
any treatment is given.
In recipients with active chronic hepatitis, with 
stable  engraftment  and  no  evidence  of  chronic 
GVHD,  treatment  with  IFN,  with  or  without 
nucleotide  analogues,  can  be  proposed
19,28.  There 
are  limited  published  data  on  the  role  of  HCV 
genotypes  on  post  transplant  liver  disease.  It  has 
been reported that genotype has no impact on the 
risk  of  liver  failure  occurring  shortly  after 
transplant
32, while it seems to influence the outcome 
of chronic hepatitis
28.
In  case  of  iron  overload,  phlebotomy  or 
chelating  agents  should  be  administered  prior  to 
Iinterferon therapy
33.Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Conclusions:  Although  effective  prevention  of 
transfusion-acquired  HBV  and  HCV  hepatitis 
should  allow  to  decrease  the  occurrence  of  such 
transplants  in  the  future,  there  are  still  some 
individual situations where  the expected long-term 
benefit  of such transplant may exceed the risk of 
liver disease. Rapid immune reconstitution and viral 
load are both involved in the mechanism of acute 
liver failure after HSCT. Such situations should be 
managed  carefully with  a special  attention during 
the  first  months  post-transplant,  and  at  any  rapid 
change  in  the  immunosuppressive  regimen. 
Quantitative  DNA  methods  of  follow-up  are  of 
paramount importance to follow the viral load.
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